:新たな進歩
Solomon L Moshé1, Emilio Perucca2, Philippe Ryvlin3
1Saul R Korey Department of Neurology, Dominick P Purpura Department of Neuroscience and Department of Pediatrics, Laboratory of Developmental Epilepsy, Montefiore/Einstein Epilepsy Management Center, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, NY, USA.
Lancet (London, England)
|September 28, 2014
まとめ
エピレプシは,世界中で何百万人もの人に影響を及ぼし,障害と高コストを引き起こす. 理解と治療の進歩にもかかわらず,多くの患者は治療に抵抗性を持ち続け,ケアと研究における重大なギャップを強調しています.
科学分野:
- 神経学 神経学とは
- クリニカル・メディシン 臨床医学
- 公衆衛生は公衆衛生である.
背景:
- エピレプシは,世界中で6500万人の個人に影響を及ぼし,障害,死亡率,併発性疾患,汚名,経済的負担という大きな課題をもたらしています.
- 近年,エピレプシーの病理生理学と予後要因の理解が進展しています.
- これにより,エピレプシーの定義,診断基準,分類システムが更新されました.
研究 の 目的:
- 現在のエピレプシー管理の状況を見直し,継続的な課題を特定する.
- 未満たされたニーズを認識しながら,理解と治療における進歩を強調する.
主な方法:
- エピレプシーの研究と臨床実務における最近の進歩に関する文献レビュー.
- 抗薬と外科介入の治療結果の分析.
- 知識,診断,治療,患者サポートにおける既存のギャップの評価.
主要な成果:
- 20年以上にわたって抗薬の使用量が大幅に増加したにもかかわらず,患者の約3分の1が薬剤耐性を示しています.
- の手術は,患者の半数以上にとって著しい発作の自由性を提供しますが,未充分に活用されています.
- 知識,診断,治療,アドボカシー,教育,立法,研究において,持続的なギャップが残っています.
結論:
- エピレプシーの管理,特に薬剤耐性症例では,依然として大きな課題が残っています.
- 手術を含む現在の治療方法は,すべての適格な患者に届いていない.
- エピレプシーのケアと研究における多面的な課題に対処するために,緊急で協調的な行動が求められます.
さらに関連する動画
関連する概念動画
01:24Epilepsy and Seizures: Overview
1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
01:22Epilepsy ll: Types
24
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
24
01:20Seizures l: Introduction
27
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
27
01:13Seizures: Classification
2.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
01:19Seizures ll: Types
23
Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
23
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K